7.1 C
Monday, December 11, 2023

New side effect of COVID-19 vaccine. The Ombudsman for Patients’ Rights has reopened compensation cases

Must read

Thromboembolism is an unwanted effect of AstraZeneca’s Vaxzevria vaccine – it has just been confirmed and the Patient Ombudsman (RPP) is reopening compensation cases. Who can apply for the money? We explain.

“Due to the confirmation that venous thromboembolism is a side effect of the Vaxevria vaccine (formerly the AstraZeneca COVID-19 vaccine), the Patient Ombudsman is ex officio reopening cases for which it was previously unable to award compensation from the Vaccination Compensation Fund . People who were hospitalized for this reason after vaccination and have not yet submitted a statement to the Ombudsman can still do so,” the IPC said in a statement.

New side effect of COVID-19 vaccine

“We urge everyone who suffered a venous thromboembolism after vaccination with the Vaxzevria/AstraZeneca vaccine, which resulted in a hospital stay of at least 14 days, to submit an application for compensation to us,” says Patient Ombudsman Bartłomiej Chmiełowiec.

As the Ombudsman emphasizes, each vaccine has proven different side effects. The main condition for the provision of financial benefits to the Patient Ombudsman is the absence after administration of the vaccine of one of the side effects listed in the so-called Summary of Product Characteristics. In justified cases, the list of side effects is supplemented and data on vaccines is updated.

In the case of Vaxevria, the list of side effects included cerebral vein thrombosis, transverse myelitis, paresthesia, hypoesthesia, tinnitus and cutaneous vasculitis. The latest change is the addition of venous thromboembolism to the list. This means that previous decisions to deny compensation may be changed in favor of patients.

Compensation for side effects of COVID-19 vaccines

Under current regulations, persons who experience an adverse reaction included in the Summary of Product Characteristics only after vaccination may apply to the Ombudsman for compensation benefits within one year of the date of this update. It will be possible to submit an application regarding the condition in question after the Vaxevria vaccine until September 21, 2024. NIZP-PZH data shows that almost 5.3 million doses of this vaccine have been administered in Poland.

As highlighted in the Monetary Policy Council statement, similar actions were taken in previous months in response to confirmation that myocarditis and pericarditis were side effects of the single-dose vaccine Jcovden (Janssen/Johnson & Johnson). People vaccinated with the Jovden vaccine who have been hospitalized for myocarditis or pericarditis can still apply for benefits through the Ombudsman.

In 2022 and the first half of 2023, the Ombudsman for Patients made a total of 223 decisions awarding compensation in connection with COVID-19 vaccinations, totaling PLN 4.5 million.

Designed by: Katarzyna Swierczyńska
Source: MPC
  • Patient area
  • Prevention
  • Coronavirus in Poland

Source: Wprost

More articles


Please enter your comment!
Please enter your name here

Latest article